东吴证券11月17日发布研报称,给予百济神州(688235.SH,最新价:165.32元)买入评级。评级理由主要包括:1)事件:销售收入快速增长,经营性现金流转正;2)BTKi领域领导者,BCL2i和BTKCDAC奠定血液瘤龙头地位;3)以替雷利珠单抗为核心,拓展实体瘤新分子。风险提示:销售收入不及预期;海外注册开发失败;和艾伯维的专利纠纷等。 AI点评:百济神州近一个月获得1份券商研报关注,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.